Guizhou Haitai Pharmaceutical Technology

Guizhou Haitai Pharmaceutical Technology is a clinical-stage biotechnology company based in Guiyang, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic disorders, with a lead program targeting hyperuricemia and gout. Its flagship candidate, HT-101, is a highly selective URAT1 inhibitor currently undergoing clinical evaluation to provide more effective treatment options for patients with elevated uric acid levels. Guizhou Haitai leverages its expertise in medicinal chemistry and pharmacology to advance its internal pipeline of novel drug candidates.